Literature DB >> 31266785

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Marlies J W Peeters1, Donata Dulkeviciute2, Arianna Draghi2, Cathrin Ritter3, Anne Rahbech2, Signe K Skadborg2, Tina Seremet2, Ana Micaela Carnaz Simões2, Evelina Martinenaite2, Hólmfridur R Halldórsdóttir2, Mads Hald Andersen2, Gitte Holmen Olofsson2, Inge Marie Svane2,4, Lene Juel Rasmussen5, Özcan Met2,4,6, Jürgen C Becker3, Marco Donia2,4, Claus Desler5, Per Thor Straten1,6.   

Abstract

The TAM family of receptor tyrosine kinases (TYRO3, AXL, and MERTK) is known to be expressed on antigen-presenting cells and function as oncogenic drivers and as inhibitors of inflammatory responses. Both human and mouse CD8+ T cells are thought to be negative for TAM receptor expression. In this study, we show that T-cell receptor (TCR)-activated human primary CD8+ T cells expressed MERTK and the ligand PROS1 from day 2 postactivation. PROS1-mediated MERTK signaling served as a late costimulatory signal, increasing proliferation and secretion of effector and memory-associated cytokines. Knockdown and inhibition studies confirmed that this costimulatory effect was mediated through MERTK. Transcriptomic and metabolic analyses of PROS1-blocked CD8+ T cells demonstrated a role of the PROS1-MERTK axis in differentiation of memory CD8+ T cells. Finally, using tumor-infiltrating lymphocytes (TIL) from melanoma patients, we show that MERTK signaling on T cells improved TIL expansion and TIL-mediated autologous cancer cell killing. We conclude that MERTK serves as a late costimulatory signal for CD8+ T cells. Identification of this costimulatory function of MERTK on human CD8+ T cells suggests caution in the development of MERTK inhibitors for hematologic or solid cancer treatment. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31266785     DOI: 10.1158/2326-6066.CIR-18-0841

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  13 in total

Review 1.  Targeting TAM to Tame Pancreatic Cancer.

Authors:  Mitchell S von Itzstein; Michael C Burke; Rolf A Brekken; Todd A Aguilera; Herbert J Zeh; Muhammad Shaalan Beg
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

2.  Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.

Authors:  Diana Llopiz; Marta Ruiz; Leyre Silva; David Repáraz; Belén Aparicio; Josune Egea; Juan J Lasarte; Esther Redin; Alfonso Calvo; Matthew Angel; Jay A Berzofsky; David Stroncek; Pablo Sarobe
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 8.679

3.  Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease.

Authors:  Lucrezia Rovati; Naoki Kaneko; Federica Pedica; Antonella Monno; Takashi Maehara; Cory Perugino; Marco Lanzillotta; Simone Pecetta; John H Stone; Claudio Doglioni; Angelo A Manfredi; Shiv Pillai; Emanuel Della-Torre
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

4.  Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells.

Authors:  Ting Lu; Li Chen; Anthony G Mansour; Melissa J Yu; Noah Brooks; Kun-Yu Teng; Zhenlong Li; Jianying Zhang; Tasha Barr; Jianhua Yu; Michael A Caligiuri
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.426

Review 5.  TAM receptors, Phosphatidylserine, inflammation, and Cancer.

Authors:  Tal Burstyn-Cohen; Avi Maimon
Journal:  Cell Commun Signal       Date:  2019-11-27       Impact factor: 5.712

6.  Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.

Authors:  Ting Lu; Rui Ma; Zhenlong Li; Anthony G Mansour; Kun-Yu Teng; Li Chen; Jianying Zhang; Tasha Barr; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2021-07-29       Impact factor: 12.020

Review 7.  Targeting phosphatidylserine for Cancer therapy: prospects and challenges.

Authors:  Wenguang Chang; Hongge Fa; Dandan Xiao; Jianxun Wang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

Review 8.  TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.

Authors:  Marlies J W Peeters; Anne Rahbech; Per Thor Straten
Journal:  Cancer Immunol Immunother       Date:  2019-10-29       Impact factor: 6.968

Review 9.  Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis.

Authors:  Anna Tutusaus; Montserrat Marí; José T Ortiz-Pérez; Gerry A F Nicolaes; Albert Morales; Pablo García de Frutos
Journal:  Cells       Date:  2020-09-28       Impact factor: 6.600

10.  Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.

Authors:  Paul Giroud; Sarah Renaudineau; Laura Gudefin; Alexandre Calcei; Thierry Menguy; Caroline Rozan; Jacques Mizrahi; Christophe Caux; Vanessa Duong; Jenny Valladeau-Guilemond
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.